Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 3, 2011, Pages 593-601

  Kapetanovic, Izet M ^a   Muzzio, Miguel ^b   Huang, Zhihua ^b   Thompson, Thomas N ^c   McCormick, David L ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b IIT RESEARCH INSTITUTE   (United States)

^c R and D Services Pharma Consulting   (United States)

Author keywords

Bioavailability; Metabolites; Pharmacokinetics; Pterostilbene; Rat; Resveratrol

Indexed keywords

DRUG METABOLITE; PTEROSTILBENE; PTEROSTILBENE GLUCURONIDE; PTEROSTILBENE SULFATE; RESVERATROL; RESVERATROL GLUCURONIDE; RESVERATROL SULFATE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALIBRATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; RATS; STILBENES; TANDEM MASS SPECTROMETRY;

EID: 80054014686     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1525-4     Document Type: Article

References (44)

1. M Abd El-Mohsen H Bayele G Kuhnle G Gibson E Debnam S Kaila Srai C Rice-Evans JP Spencer 2006 Distribution of [3H]trans-resveratrol in rat tissues following oral administration Br J Nutr 96 62 70 16869992 10.1079/BJN20061810 1:CAS:528:DC%2BD28XovFKqtbY%3D
2. M Athar JH Back L Kopelovich DR Bickers AL Kim 2009 Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms Arch Biochem Biophys 486 95 102 19514131 10.1016/j.abb.2009.01.018 1:CAS:528:DC%2BD1MXmvF2hurY%3D
3. M Athar JH Back X Tang KH Kim L Kopelovich DR Bickers AL Kim 2007 Resveratrol: a review of preclinical studies for human cancer prevention Toxicol Appl Pharmacol 224 274 283 17306316 10.1016/j.taap.2006.12.025 1:CAS:528:DC%2BD2sXhtF2mtL7K
4. JA Baur DA Sinclair 2006 Therapeutic potential of resveratrol: the in vivo evidence Nat Rev Drug Discov 5 493 506 16732220 10.1038/nrd2060 1:CAS:528:DC%2BD28XlsV2jur8%3D
5. A Bishayee 2009 Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials Cancer Prev Res 2 409 418 10.1158/1940-6207. CAPR-08-0160 1:CAS:528:DC%2BC3cXptFOisro%3D
6. DJ Boocock GES Faust KR Patel AM Schinas VA Brown MP Ducharme TD Booth JA Crowell M Perloff AJ Gescher WP Steward DE Brenner 2007 Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent Cancer Epidemiol Biomarkers Prev 16 1246 1252 17548692 10.1158/1055-9965.EPI-07-0022 1:CAS:528:DC%2BD2sXmtVKntLY%3D
7. F Brisdelli G D'Andrea A Bozzi 2009 Resveratrol: a natural polyphenol with multiple chemopreventive properties (Review) Curr Drug Metab 10 530 546 19702538 1:CAS:528:DC%2BD1MXhsVSku7bK
8. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas A, Piccirilli G, Brown K, Steward W, Gescher AJ, Brenner DE (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res [Epub ahead of print]
9. B Calamini K Ratia MG Malkowski M Cuendet JM Pezzuto BD Santarsiero AD Mesecar 2010 Pleiotropic mechanisms facilitated by resveratrol and its metabolites Biochem J 429 2 273 282 20450491 10.1042/BJ20091857 1:CAS:528:DC%2BC3cXotVajs7Y%3D
10. Chakraborty A, Gupta N, Ghosh K, Roy P (2010) In vitro evaluation of the cytotoxic, anti-proliferative and anti-oxidant properties of pterostilbene isolated from Pterocarpus marsupium. Toxicol Vitr 24:1215-1228
11. DK Das 2006 Resveratrol in cardioprotection: a therapeutic promise of alternative medicine Mol Interv 6 36 47 16507749 10.1124/mi.6.1.7 1:CAS:528:DC%2BD28Xjt1Gls7g%3D
12. S Das HS Lin PC Ho KY Ng 2008 The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol Pharm Res 25 2593 2600 18629618 10.1007/s11095-008-9677-1 1:CAS:528:DC%2BD1cXht1aisb3O
13. C De Santi A Pietrabissa R Spisni F Mosca GM Pacifici 2000 Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum Xenobiotica 30 609 617 10923862 10.1080/004982500406435
14. N Gamage A Barnett N Hempel RG Duggleby KF Windmill JL Martin ME McManus 2006 Human sulfotransferases and their role in chemical metabolism Toxicol Sci 90 5 22 16322073 10.1093/toxsci/kfj061 1:CAS:528:DC%2BD28XhtlOnt78%3D
15. SK Goswami DK Das 2009 Resveratrol and chemoprevention Cancer Lett 284 1 6 19261378 10.1016/j.canlet.2009.01.041 1:CAS:528:DC%2BD1MXhtVKlsLjL
16. J Hoshino EJ Park TP Kondratyuk L Marler JM Pezzuto RB van Breemen S Mo Y Li M Cushman 2010 Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites J Med Chem 53 5033 5043 20527891 10.1021/jm100274c 1:CAS:528:DC%2BC3cXntF2jt7w%3D
17. M Jang L Cai GO Udeani KV Slowing CF Thomas CW Beecher HH Fong NR Farnsworth AD Kinghorn RG Mehta RC Moon JM Pezzuto 1997 Cancer chemopreventive activity of resveratrol, a natural product derived from grapes Science 275 218 220 8985016 10.1126/science.275.5297.218 1:CAS:528:DyaK2sXks1Sjtw%3D%3D
18. TE Kraft D Parisotto C Schempp T Efferth 2009 Fighting cancer with red wine? Molecular mechanisms of resveratrol Crit Rev Food Sci Nutr 49 782 799 20443159 10.1080/10408390802248627 1:CAS:528:DC%2BD1MXht1WhtL%2FP
19. G Kuhnle JP Spencer G Chowrimootoo H Schroeter ES Debnam SK Srai C Rice-Evans U Hahn 2000 Resveratrol is absorbed in the small intestine as resveratrol glucuronide Biochem Biophys Res Commun 272 212 217 10872829 10.1006/bbrc.2000.2750 1:CAS:528:DC%2BD3cXkt1ansbo%3D
20. JK Kundu YJ Surh 2008 Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives Cancer Lett 269 243 261 18550275 10.1016/j.canlet.2008.03.057 1:CAS:528:DC%2BD1cXhtFWlsrjO
21. P Langcake 1981 Disease resistance of Vitis spp. and the production of the stress metabolites resveratrol, epsilon-viniferin, alpha-viniferin and pterostilbene Physiol Plant Pathol 18 213 226 1:CAS:528:DyaL3MXhvVykurs%3D
22. C la Porte N Voduc G Zhang I Seguin D Tardiff N Singhal DW Cameron 2010 Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects Clin Pharmacokinet 49 7 449 454 20528005 10.2165/11531820-000000000-00000 1:CAS:528:DC%2BC3cXhtV2ns7rF
23. H-S Lin B-D Yue PC Ho 2009 Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study Biomed Chromatogr 23 1308 1315 19488981 10.1002/bmc.1254 1:CAS:528:DC%2BD1MXhsVWht73L
24. Mannal PW, Alosi JA, Schneider JG, McDonald DE, McFadden DW (2010) Pterostilbene inhibits pancreatic cancer in vitro. J Gastrointest Surg 14:873-879
25. JF Marier P Vachon A Gritsas J Zhang JP Moreau MP Ducharme 2002 Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model J Pharmacol Exp Ther 302 369 373 12065739 10.1124/jpet.102.033340 1:CAS:528:DC%2BD38Xlt1SnsLg%3D
26. FZ Marques MA Markus BJ Morris 2009 Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits Int J Biochem Cell Biol 41 2125 2128 19527796 10.1016/j.biocel.2009.06.003 1:CAS:528:DC%2BD1MXhtFyntL3P
27. Z Pan AK Agarwal T Xu Q Feng SR Baerson SO Duke AM Rimando 2008 Identification of molecular pathways affected by pterostilbene, a natural dimethylether analog of resveratrol BMC Med Genomics 1 7 18366703 10.1186/1755-8794-1-7
28. S Paul A DeCastro HJ Lee AK Smolarek JY So B Simi CX Wang R Zhou AM Rimando N Suh 2010 Dietary intake of pterostilbene, a constituent of blueberries, inhibits the {beta}-catenin/p65 downstream signaling pathway and colon carcinogenesis in rats Carcinogenesis 31 1272 1278 20061362 10.1093/carcin/bgq004 1:CAS:528:DC%2BC3cXotlChtrw%3D
29. S Paul AM Rimando HJ Lee Y Ji BS Reddy N Suh 2009 Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells Cancer Prev Res 2 650 657 10.1158/1940-6207.CAPR-08-0224 1:CAS:528:DC%2BC3cXptFKnsrg%3D
30. S Pervaiz AL Holme 2009 Resveratrol: its biologic targets and functional activity Antioxid Redox Signal 11 2851 2897 19432534 10.1089/ars.2008.2412 1:CAS:528:DC%2BD1MXht1Ojt7bP
31. JM Pezzuto 2008 Resveratrol as an inhibitor of carcinogenesis Pharm Biol 46 443 573 10.1080/13880200802116610 1:CAS:528:DC%2BD1cXnsVCksLo%3D
32. L Pirola S Frojdo 2008 Resveratrol: one molecule, many targets IUBMB Life 60 323 332 18421779 10.1002/iub.47 1:CAS:528:DC%2BD1cXhtlKiur3K
33. AM Rimando M Cuendet C Desmarchelier RG Mehta JM Pezzuto SO Duke 2002 Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol J Agric Food Chem 50 3453 3457 12033810 10.1021/jf0116855 1:CAS:528:DC%2BD38XjsVygt7s%3D
34. AM Rimando N Suh 2008 Biological/chemopreventive activity of stilbenes and their effect on colon cancer Planta Med 74 1635 1643 18843589 10.1055/s-0028-1088301 1:CAS:528:DC%2BD1cXhtl2hsbrM
35. P Saiko A Szakmary W Jaeger T Szekeres 2008 Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res Rev Mutat Res 658 68 94 1:CAS:528:DC%2BD1cXhsVGku7g%3D
36. L Schmidlin A Poutaraud P Claudel P Mestre E Prado M Santos-Rosa S Wiedemann-Merdinoglu F Karst D Merdinoglu P Hugueney 2008 A stress-inducible resveratrol O-methyltransferase involved in the biosynthesis of pterostilbene in grapevine Plant Physiol 148 1630 1639 18799660 10.1104/pp.108.126003 1:CAS:528:DC%2BD1cXhsVSnurbO
37. S Shankar G Singh RK Srivastava 2007 Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential Front Biosci 12 4839 4854 17569614 10.2741/2432 1:CAS:528:DC%2BD2sXosF2ru74%3D
38. N Suh S Paul X Hao B Simi H Xiao AM Rimando BS Reddy 2007 Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats Clin Cancer Res 13 350 355 17200374 10.1158/1078-0432.CCR-06-1528 1:CAS:528:DC%2BD2sXotlal
39. RH Tukey CP Strassburg 2000 Human UDP-glucuronosyltransferases: metabolism, expression, and disease Annu Rev Pharmacol Toxicol 40 581 616 10836148 10.1146/annurev.pharmtox.40.1.581 1:CAS:528:DC%2BD3cXjs1yht7k%3D
40. K van de Wetering A Burkon W Feddema A Bot H de Jonge V Somoza P Borst 2009 Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol Mol Pharmacol 75 876 885 19114588 10.1124/mol.108.052019
41. T Walle F Hsieh MH DeLegge JE Oatis Jr. UK Walle 2004 High absorption but very low bioavailability of oral resveratrol in humans Drug Metab Dispos 32 1377 1382 15333514 10.1124/dmd.104.000885 1:CAS:528:DC%2BD2cXhtFGitrfE
42. X Wen T Walle 2006 Methylated flavonoids have greatly improved intestinal absorption and metabolic stability Drug Metab Dispos 34 1786 1792 16868069 10.1124/dmd.106.011122 1:CAS:528:DC%2BD28XhtVCltbjN
43. E Wenzel T Soldo H Erbersdobler V Somoza 2005 Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats Mol Nutr Food Res 49 482 494 15779067 10.1002/mnfr.200500003 1:CAS:528:DC%2BD2MXlvFOksr0%3D
44. E Wenzel V Somoza 2005 Metabolism and bioavailability of trans-resveratrol Mol Nutr Food Res 49 472 481 15779070 10.1002/mnfr.200500010 1:CAS:528:DC%2BD2MXlvFOksrw%3D